Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia.

Blood
Wael SaberJeff Schriber

Abstract

Approximately one-third of patients with an indication for hematopoietic cell transplantation (HCT) have an HLA-matched related donor (MRD) available to them. For the remaining patients, a matched unrelated donor (MUD) is an alternative. Prior studies comparing MRD and MUD HCT provide conflicting results, and the relative efficacy of MRD and MUD transplantation is an area of active investigation. To address this issue, we analyzed outcomes of 2223 adult acute myelogenous leukemia patients who underwent allogeneic HCT between 2002 and 2006 (MRD, n = 624; 8/8 HLA locus matched MUD, n = 1193; 7/8 MUD, n = 406). The 100-day cumulative incidence of grades B-D acute GVHD was significantly lower in MRD HCT recipients than in 8/8 MUD and 7/8 MUD HCT recipients (33%, 51%, and 53%, respectively; P < .001). In multivariate analysis, 8/8 MUD HCT recipients had a similar survival rate compared with MRD HCT recipients (relative risk [RR], 1.03; P = .62). 7/8 MUD HCT recipients had higher early mortality than MRD HCT recipients (RR, 1.40; P < .001), but beyond 6 months after HCT, their survival rates were similar (RR, 0.88; P = .30). These results suggest that transplantation from MUD and MRD donors results in similar survival times for patie...Continue Reading

References

Aug 1, 1980·The American Journal of Medicine·H M ShulmanE D Thomas
Jan 7, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S J LeeJ H Antin
Aug 11, 2000·BMJ : British Medical Journal·A L Lennard, G H Jackson
Dec 5, 2002·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Edwin P AlyeaRobert J Soiffer
Jun 21, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Christopher L HallemeierDouglas R Adkins
Nov 7, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Jennifer R BrownEdwin P Alyea
Jul 21, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·John KuruvillaKevín W Song
Aug 29, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mohamed L SorrorRainer Storb
Sep 14, 2007·Computer Methods and Programs in Biomedicine·Xu ZhangMei-Jie Zhang
Jan 25, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Ginna G LaportRainer F Storb
Sep 6, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Chatchada KaranesDennis L Confer
Sep 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mohamed L SorrorDavid G Maloney
Feb 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mukta AroraEffie W Petersdorf
Oct 14, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Daniel J WeisdorfUNKNOWN Chronic Leukemia Working Committee
Dec 17, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ziyi LimTheo M De Witte
Mar 17, 2010·Bone Marrow Transplantation·S PalluaB Holzner
May 8, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Ann WoolfreyEffie Petersdorf
Jan 5, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Vincent T HoEdwin P Alyea
May 14, 2011·International Journal of Health Care Finance and Economics·Timothy F Page

❮ Previous
Next ❯

Citations

Aug 21, 2013·Current Oncology Reports·John Magenau, Daniel R Couriel
Dec 7, 2013·Best Practice & Research. Clinical Haematology·Daniel Weisdorf
Jun 25, 2013·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Jieun Uhm, John Kuruvilla
Oct 19, 2012·The New England Journal of Medicine·Frederick R Appelbaum
Aug 11, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Navneet S MajhailUNKNOWN American Society for Blood and Marrow Transplantation
Oct 14, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Kavita Raj
Sep 13, 2012·British Journal of Haematology·Jeffrey E Rubnitz, Hiroto Inaba
Aug 5, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Christopher G Kanakry, Leo Luznik
Jun 24, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Betul OranRichard E Champlin
Jun 23, 2015·Cancer·Dolores A GrossoMark A Weiss
Jun 3, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Moshe YeshurunRon Ram
Apr 8, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Amir A ToorMichael C Neale
Feb 26, 2016·American Journal of Hematology·Takaaki KonumaUNKNOWN Donor/Source Working Group of the Japan Society for Hematopoietic Cell Transplantation
Dec 4, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Mario DeliaGiorgina Specchia
Sep 14, 2013·Blood·Nicolaus Kröger
Jan 11, 2014·Blood·Marcelo A Fernandez-ViñaMichelle Setterholm

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.